{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:12Z","timestamp":1791607752817,"version":"4.3.4"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8138-26","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:11:59Z","timestamp":1791411119000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Review of Renovascular Hypertension and Hypertensive Emergency-related Nephropathy Based on Case Series"],"prefix":"10.2169","author":[{"given":"Yoshifumi","family":"Ubara","sequence":"first","affiliation":[{"name":"Nephrology Center, Toranomon Hospital, Japan"},{"name":"The Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital, Japan"},{"name":"The Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Farris AB. Hypertensive renovascular diseases. In: Diagnostic Pathology Kidney Disease. fourth ed. Colvin R, Chang A, et al., Eds. Elsevier, Philadelphia, 2023: 618-662."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Oshima Y, Sawa N, Yamanouchi M, et al. Clinicopathological cohort study of kidney biopsy findings resulting in dialysis during long-term follow-up exceeding 30 years. Clin Exp Nephrol 29: 1637-1652, 2025.","DOI":"10.1007\/s10157-025-02706-8"},{"key":"3","unstructured":"3. Ubara Y, Hara S, Katori H, Yamada A, Morii H. Renovascular hypertension may cause nephrotic range proteinuria and focal glomerulosclerosis in contralateral kidney. Clin Nephrol 48: 220-223, 1997."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Thadhani R, Pascual M, Nickeleit V, Tolkoff-Rubin N, Colvin R. Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet 347: 231-233, 1996.","DOI":"10.1016\/S0140-6736(96)90406-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Iwami D, Harada H, Usubuchi H, et al. Regional secondary focal segmental glomerulosclerosis in a transplanted kidney: resolution with treatment of a segmental renal artery stenosis. BMC Nephrol 13: 38, 2012.","DOI":"10.1186\/1471-2369-13-38"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ubara Y, Kawaguchi T, Nagasawa T, et al.; Committee of Practical Guide for Kidney Biopsy 2020. Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol 25: 325-364, 2021.","DOI":"10.1007\/s10157-020-01986-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sarafidis PA, Theodorakopoulou M, Ortiz A, et al. Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Nephrol Dial Transplant 38: 2835-2850, 2023.","DOI":"10.1093\/ndt\/gfad095"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Boulestreau R, van den Born BH, Lip GYH, Gupta A. Malignant hypertension: current perspectives and challenges. J Am Heart Assoc 11: e023397, 2022.","DOI":"10.1161\/JAHA.121.023397"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsige AW, Ayele SG. Malignant hypertension: current challenges, prevention strategies, and future perspectives. Front Cardiovasc Med 11: 1409212, 2024.","DOI":"10.3389\/fcvm.2024.1409212"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nonaka K, Ubara Y, Sumida K, et al. Clinical and pathological evaluation of hypertensive emergency-related nephropathy. Intern Med 52: 45-53, 2013.","DOI":"10.2169\/internalmedicine.52.7398"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ubara Y, Kurihara S, Tsuchiya Y, et al. A case of hypertensive emergency with alveolar hemorrhage and thrombotic microangiopathy. CEN Case Rep 13: 450-456, 2024.","DOI":"10.1007\/s13730-024-00863-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sawamura M, Sawa N, Oshima Y, et al. A case of malignant nephrosclerosis occurring with serum renin in the normal range. CEN Case Rep 2023.","DOI":"10.1007\/s13730-022-00726-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617-1620, 1985.","DOI":"10.1056\/NEJM198512263132601"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Parving HH, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.","DOI":"10.1056\/NEJMoa011489"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.","DOI":"10.1056\/NEJMoa011161"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Remuzzi G, Ruggenenti P, Perna A, et al.; RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15: 3117-3125, 2004.","DOI":"10.1097\/01.ASN.0000146423.71226.0C"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001.","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18: 1959-1965, 2007.","DOI":"10.1681\/ASN.2006101081"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fu EL, Evans M, Clase CM, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol 32: 424-435, 2021.","DOI":"10.1681\/ASN.2020050682"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nagai Y, Yamabe F, Sasaki Y, et al. A study of morphological changes in renal afferent arterioles induced by angiotensin II type 1 receptor blockers in hypertensive patients. Kidney Blood Press Res 45: 194-208, 2020.","DOI":"10.1159\/000505025"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nakanishi K, Nagai Y, Honglan Piao, et al. Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats. J Renin Angiotensin Aldosterone Syst 12: 65-74, 2011.","DOI":"10.1177\/1470320310387844"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Watanabe H, Martini AG, Brown RI, et al. Inhibition of the renin-angiotensin system causes concentric hypertrophy of renal arterioles in mice and humans. JCI Insight 6: e154337, 2021.","DOI":"10.1172\/jci.insight.154337"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446, 2008.","DOI":"10.1056\/NEJMoa0708379"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Messerli FH, Bangalore S. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point. Am J Med 126: e1-3, 2013.","DOI":"10.1016\/j.amjmed.2012.07.006"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8138-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:11:35Z","timestamp":1791605495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8138-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8138-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8138-26"}}